The difference in these findings may reflect variations between trials in disease duration (e.g. patients with early RA versus patients with established RA) and treatment history (e.g. biologic naïve versus biologic experienced, MTX responders versus those with an inadequate MTX response and TNF-inhibitor responders versus non-responders). This evidence concerns the gene TNF and rheumatoid arthritis.